Singapore markets open in 1 hour 41 minutes

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.0700+0.2523 (+30.85%)
At close: 03:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.8177
Open0.8495
BidN/A x N/A
AskN/A x N/A
Day's range0.8495 - 1.0700
52-week range0.6761 - 1.8000
Volume10,890
Avg. volume16,417
Market cap63.4M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.3780
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Alpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury

    VANCOUVER, British Columbia, December 06, 2021--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program. ALPHA-1062 administration significantly, acutely reduced the extent of the functional

  • Business Wire

    Alpha Cognition Appoints Cedric O’Gorman, M.D., MBA as Chief Medical Officer

    VANCOUVER, British Columbia, December 02, 2021--Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer. Dr. O’Gorman will lead medical, clinical and regulatory functions in support of the company's clinic

  • Business Wire

    Alpha Cognition Reports Third Quarter of Fiscal 2021 Results

    VANCOUVER, British Columbia, November 30, 2021--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it has reported its Third Quarter financial results of fiscal 2021.